Finance

Lists
Q1 2027 earnings • released • EPS miss -41.60% • Revenue miss -0.51%
See results
RDY:NYSE
Dr Reddy's Laboratories Ltd
$11.79
+0.63%
(+0.073) 1D
$11.79
0.00% (0.00)
After hours
Closed: Jul 24, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
$11.80
High
$11.98
Low
$11.68
Mkt. cap
10.05B
Avg. vol.
2.89M
Volume
3.23M
Dividend
0.71%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
28.66
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.41
Beta
0.27
Shares outstanding
834.64M
No. of employees
28K
Open
$11.80
High
$11.98
Low
$11.68
Mkt. cap
10.05B
Avg. vol.
2.89M
Volume
3.23M
Dividend
0.71%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
28.66
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.41
Beta
0.27
Shares outstanding
834.64M
No. of employees
28K
News stories
From sources across the web
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com
Analyst ratings
Based on 1 analyst giving stock ratings to RDY in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for RDY in the last 3 months
Highest
Current $11.79
$15.95 (+35.26%)
Average
$15.95 (+35.28%)
Lowest
$15.95 (+35.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Neha Manpuria
Bank of America Securities
Buy
Reiterated
₹1,540.00
+12,961.9%
06/18/2026
Unknown Analyst
Citi
Sell
Maintained
-
-
04/23/2026
Last report
Jul 22, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹5.33 / ₹9.13
-41.60%miss
Revenue / Est. (INR)
80.70B / 81.12B
-0.51%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
88.05B
87.27B
75.16B
80.70B
Cost of goods sold
39.91B
40.46B
41.47B
43.16B
Cost of revenue
39.91B
40.46B
41.47B
43.16B
Research and development expenses
6.20B
6.15B
5.46B
5.77B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.44B
26.92B
27.76B
28.82B
Operating expense
31.90B
32.48B
32.53B
34.11B
Total operating expenses
71.81B
72.94B
74.00B
77.27B
Operating income
16.24B
14.33B
1.16B
3.43B
Other non operating income
1.28B
570.00M
512.00M
-
EBT including unusual items
18.35B
15.43B
1.99B
5.53B
EBT excluding unusual items
17.81B
15.52B
1.82B
4.09B
Income tax expense
4.08B
3.53B
-214.00M
1.18B
Effective tax rate
22.24%
22.90%
-10.75%
21.32%
Other operating expenses
-740.00M
-591.00M
-693.00M
-477.00M
Net income
14.37B
12.10B
2.20B
4.44B
Net profit margin
16.32%
13.86%
2.93%
5.50%
Earnings per share
17.87
14.77
5.74
5.33
Interest and investment income
912.00M
796.00M
890.00M
999.00M
Interest expense
-907.00M
-944.00M
-1.06B
-1.26B
Net interest expenses
5.00M
-148.00M
-167.00M
-256.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
21.29B
19.54B
5.03B
8.80B
Gain or loss from assets sale
-308.00M
-179.00M
-2.10B
-368.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer